BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.
BAP1
PARP inhibitors
chemotherapy
immune check-point inhibitors
mesothelioma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
09
2020
accepted:
05
01
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
Little is known regarding the outcomes of systemic treatments in BAP1-altered malignant pleural mesothelioma (MPM). Forty five patients with MPM [group A: eight MPM patients with BAP1 inactivating mutation/copy number loss (FoundationOne There were no differences in ORR or mPFS with CT between the groups: ORR-50% BAP1-altered MPM, as compared to non-selected MPM, is characterized by similar efficacy of CT and ICPi. Numerically longer OS in BAP1-altered MPM may reflect favorable tumor biology. No responses were observed with PARPi.
Identifiants
pubmed: 33777745
doi: 10.3389/fonc.2021.603223
pmc: PMC7987904
doi:
Types de publication
Journal Article
Langues
eng
Pagination
603223Informations de copyright
Copyright © 2021 Dudnik, Bar, Moore, Gottfried, Moskovitz, Dudnik, Shochat, Allen, Zer, Rotem, Peled and Urban.
Déclaration de conflit d'intérêts
ED reported grants from Boehringer Ingelheim, personal fees for consulting or advisory services from Boehringer Ingelheim, Roche, Astra Zeneca, Pfizer, MSD, BMS, Novartis, Takeda. JB reported grants from MSD, Roche, Boehringer Ingelheim, AstraZeneca and Pfizer, and personal fees for consulting or advisory services from MSD, Roche, Boehringer Ingelheim, AstraZeneca, Pfizer, BMS, Novartis, Takeda, Bayer, Vascular Biogenics, and Abbvie. AM reported honoraria from Merck, Roche. MM reported personal fees for consulting or advisory services from Boehringer Ingelheim, Roche, Astra Zeneca, MSD, BMS, and Takeda. AZ reported grants from BMS, personal fees for consulting or advisory services from Roche, MSD, BMS, Astra Zeneca. NP reported grants and personal fees for consulting or advisory services from Astra Zeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Roche, Pfizer, Novartis, NovellusDx, FMI, Gaurdant360. DU reported personal fees for consulting or advisory services from Boehringer Ingelheim, Roche, Astra Zeneca, MSD, BMS, Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
Ann Oncol. 2008 Feb;19(2):370-3
pubmed: 18156144
Thorax. 2000 Sep;55(9):731-5
pubmed: 10950889
Lancet Oncol. 2015 Apr;16(4):447-56
pubmed: 25800891
Carcinogenesis. 2015 Jan;36(1):76-81
pubmed: 25380601
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):285-90
pubmed: 24347639
Int J Mol Sci. 2019 Jan 19;20(2):
pubmed: 30669483
J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341
pubmed: 30517737
Clin Cancer Res. 2019 Sep 15;25(18):5485-5492
pubmed: 31164373
J Thorac Oncol. 2015 Mar;10(3):492-9
pubmed: 25514803
JAMA Oncol. 2019 Mar 1;5(3):351-357
pubmed: 30605211
Lung Cancer. 2015 Jan;87(1):77-9
pubmed: 25468148
J Thorac Oncol. 2008 Jul;3(7):756-63
pubmed: 18594322
J Transl Med. 2012 Aug 30;10:179
pubmed: 22935333
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Ann Oncol. 2015 Sep;26 Suppl 5:v31-9
pubmed: 26223247
J Thorac Oncol. 2016 Nov;11(11):1863-1868
pubmed: 27664534
Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867
pubmed: 28756516
J Clin Oncol. 2018 Oct 30;:JCO2018790352
pubmed: 30376426
Oncotarget. 2015 May 30;6(15):13757-71
pubmed: 25970771
J Thorac Oncol. 2015 Apr;10(4):565-76
pubmed: 25658628
Lancet Oncol. 2017 May;18(5):623-630
pubmed: 28291584
J Clin Oncol. 2006 Mar 20;24(9):1443-8
pubmed: 16549838
Chest. 1998 Mar;113(3):723-31
pubmed: 9515850
Lung Cancer. 2019 Jan;127:164-166
pubmed: 30642545
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Genome Med. 2019 Feb 18;11(1):8
pubmed: 30777124
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Nat Genet. 2011 Aug 28;43(10):1022-5
pubmed: 21874000
J Thorac Oncol. 2013 Nov;8(11):1430-3
pubmed: 24128712
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
Clin Cancer Res. 2014 Mar 1;20(5):1323-34
pubmed: 24443521
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9008-9013
pubmed: 30975761
J Clin Oncol. 1998 Jan;16(1):145-52
pubmed: 9440736
J Oncol Pract. 2018 Apr;14(4):256-264
pubmed: 29517955
Mol Oncol. 2020 Jun;14(6):1207-1223
pubmed: 32083805
J Thorac Oncol. 2018 Oct;13(10):1569-1576
pubmed: 29908324
Cancer Res. 2015 Jan 15;75(2):264-9
pubmed: 25488749
Nat Genet. 2011 Jun 05;43(7):668-72
pubmed: 21642991
Pathology. 2013 Dec;45(7):651-6
pubmed: 24247622
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
J Thorac Oncol. 2017 Apr;12(4):724-733
pubmed: 28034829
J Occup Med. 1992 Jul;34(7):718-21
pubmed: 1494965
Nature. 2010 May 13;465(7295):243-7
pubmed: 20436459
Ann Oncol. 2004 Feb;15(2):257-60
pubmed: 14760119
Lancet Respir Med. 2018 Jun;6(6):451-460
pubmed: 29773326
J Thorac Oncol. 2017 Aug;12(8):1309-1319
pubmed: 28389374
Clin Cancer Res. 2012 Jan 1;18(1):77-90
pubmed: 22028491
J Clin Oncol. 2018 Oct 1;36(28):2863-2871
pubmed: 30113886